The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.5 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Lectures Included

• Disease State Network Year-in-Review: Diabetes - Cecilia Low Wang, MD and Rifka Schulman-Rosenbaum, MD, FACE, CNSC
• Personalized Pharmacotherapy for Patients with T2D - Lawrence Blonde, MD, FACP, MACE and Guillermo Umpierrez, MD, MACP, CDCES, FACE
• SGLT2 inhibitors: Hot Topics and Challenges - Guillermo Umpierrez, MD, MACP, CDCES, FACE
• Diabetes Technologies in 2022 - Archana Sadhu, MD, FACE
• Managing T2DM in CKD - Rodolfo J. Galindo, MD, FACE
• What's New in the Management of the Diabetic Kidney? A Pro/Con Debate - Katherine Tuttle, MD, FASN, FACP, FNKF; Robert Stanton, MD
• Diagnosis and Investigation of Diabetes Insipidus - Natasa Janicic Kahric, MD

Learning Objectives

Upon completion of the activity, participants should be able to:

• Identify important research published in the past year regarding diabetes pharmacotherapy, cardiovascular and renal outcomes, inpatient diabetes management, diabetes technology, and access to healthcare
• Review results of recent randomized control trials on the safety and efficacy of anti-diabetic agents for cardiovascular and renal protection and identify AACE recommendations for the management of obesity, hypertension, hyperlipidemia and cardiovascular risk factors in patients with diabetes
• Assess the current issues and challenges with SGLT2 inhibitors

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

• Cecilia C Low Wang, MD - Professor of Medicine University of Colorado Anschutz Medical Campus School of Medicine: Dexcom Inc (Self) : Research Grant (Status: Ongoing)
  
• Rifka Schulman-Rosenbaum, MD, FACE, CNSC - Director of Inpatient Diabetes, Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Long Island Jewish Medical Center, and Barbara Zucker School of Medicine at Hofstra/Northwell: Nothing to disclose.
  
• Lawrence Blonde, MD, FACP, MACE - Ochsner Medical Center: AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- No activities in the past 24 months); Corcept (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Gilead Sciences, Inc. (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Janssen () : Honorarium, speaker; Lyndra Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck & Co (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Salix (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing)
  
• Guillermo E Umpierez, MD, MACP, CDCES, FACE - Professor of Medicine Emory University: Astra Zeneca (Self) : Grant support to Emory University for investigator-initiated clinical studies (Status: Ongoing), University Grants/Research Support (Status: Ongoing); Dexcom (Self) : University Grants/Research Support (Status: Ongoing); Novo Nordisk (Self) : Grant support to Emory University for investigator-initiated clinical studies (Status: Terminated --- December 2020), University Grants/Research Support (Status: Terminated --- December 2020); Sanofi,Merck, Novo Nordisk, Astra Zeneca, Boehringer Ingelheim (Self) : Received grant support (to Emory university) for investigator-initiated research studies from Sanofi, Novo Nordisk, Astra Zeneca, Merck and Boehringer Ingelheim. (Status: Terminated --- January 2019), Research Grant (Status: Terminated --- January 2019)
  
• Archana Sadhu, MD, FACE - Director, System Diabetes Program and Director, Transplant Endocrinology Houston Methodist: Abbott (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
  
• Rodolfo J Galindo MD, FACE - Emory University: Abbott Diabetes (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/31/2018); Dexcom (Self) : University Grants/Research Support (Status: Ongoing); Eli Lilly (Self) : Research Grant (Status: Ongoing); Novo Nordisk (Self) : University Grants/Research Support (Status: Ongoing); Sanofi (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Valeritas (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/31/2019); Weight Watchers (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
  
• Neda Rasouli, MD - University of Colorado: Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
  
• Katherine R Tuttle, MD, FASN, FACP, FNKF - Professor of Medicine University of Washington: AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Bayer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Eli Lilly (Self) : Honorarium (Status: Ongoing); Gilead (Self) : Grant/Research Support (Status: Ongoing); Goldfinch Bio (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Grant/Research Support (Status: Ongoing); Travere (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
  
• Natasa Janicic Kahric, MD - Associate Professor Medstar Georgetown University Hospital: DEXCOM (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
  
• Scott D Isaacs, MD, FACP, FACE - Adjunct Assistant Professor of Medicine Emory University School of Medicine: Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Medpace (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Quest (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21)
  
• Kenneth Cusi, MD, FACP, FACE - Chief of the Division of Endocrinology UFL: Allergan Pharmaceuticals (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Axcellla (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); BMS (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Cirius (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Coherus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Deuterex (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Echosens (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Fractyl (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genentech (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genfit (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); High Tide (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2021); Inventiva (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Janssen (Self) : Research Grant (Status: Terminated --- 2020); Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); National Institutes of Health (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Nordic (Self) : Research Support (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Poxel (Self) : Research Grant (Status: Terminated --- 2021); Prosciento (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi-Adventis (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Viscera Labs (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Zydus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

• Cecilia C. Low Wang, MD
• Rifka Schulman-Rosenbaum, MD, FACE, CNSC
• Lawrence Blonde, MD, FACP, MACE
• Guillermo E. Umpierrez, MD, MACP, CDCES, FACE
• Archana Sadhu, MD, FACE
• Rodolfo J. Galindo, MD, FACE
• Katherine R. Tuttle, MD, FASN, FACP, FNKF
• Robert Stanton, MD
• Natasa Janicic Kahric, MD
• Kenneth Cusi, MD, FACP, FAC